A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Company facts
| Company | AstraZeneca PLC |
|---|---|
| Symbol | AZN |
| Exchange | XNYS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $247.59B (Massive market data, 2026-09-10) |
| Employees | 96,100 |
| Country | United Kingdom |
| Website | https://www.astrazeneca.com |
Trading — AstraZeneca PLC
| Last price | $155.00 |
|---|---|
| Change | -2.91% |
| Previous close | $159.64 |
| Day range | $158.13 – $161.51 |
| 50-day average | $169.10 |
| 200-day average | $183.89 |
| Average volume | 2,690,395 |
Price basis: 2026-09-11T21:02:00.031637+00:00
Valuation and financial health
| Earnings per share | $1.43 |
|---|---|
| Price / book | 18.30 |
| Price / cash flow | 67.10 |
| Enterprise value / EBITDA | 49.32 |
| Enterprise value / sales | 10.92 |
| Debt / equity | 1.40 |
| Current ratio | 0.93 |
| Dividend yield | 1.43% |
| Free cash flow | $2.27B |
| Cash ratio | 0.27 |
| Enterprise value | $262.67B |
Reported 2026-09-10
Earnings
| Report date | 2026-10-30 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | 2026-09-30 |
| EPS estimate | 2.62 |
Source: optionsai supplemental public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for AZN are on the IntelTrends dashboard.